PillRx only · Injection, Powder, Lyophilized, For Solution · Intramuscular
Colistimethate Sodium
Colistimethate Sodium
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US2 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$15.487
Latest avg · May 20, 2026
-14%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
263
Rx · 2026 Q1
9.0K
Units dispensed
+5%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | unknown | 2 | SUPPLYING |
| Fresenius Kabi USA, LLC | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Feb 25, 2015RECALLRecall (Class II): Colistimethate for Injection USP, 150 mg per vial, Rx Only, Manufactured by: Emcure Pharmaceuticals Ltd., Hinjwadi, Pu…
Lack of Assurance of Sterility: Firm is recalling two injectable products due to concerns with quality control processes. — Recalling firm: Heritage Pharmaceuticals, Inc. — Nationwide